ABBV vs REGN
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases.
Side-by-side fundamentals
| Metric | ABBV | REGN | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $264.96 | $834.04 | |
| Market cap as of 2026-08-24 | $468.2B | $78.4B | |
| P/E as of 2026-08-24 | 70.24 | 18.98 | REGN lower |
| PEG as of 2026-08-24 | 6.59 | 1.08 | REGN lower |
| Net margin as of 2026-08-24 | +9.8% | +27.9% | REGN higher |
| Gross margin as of 2026-08-24 | +72.8% | +86.0% | REGN higher |
| Operating margin as of 2026-08-24 | +26.2% | +24.7% | ABBV higher |
| ROE as of 2026-08-24 | +95.6% | +13.8% | ABBV higher |
| ROA as of 2026-08-24 | +4.7% | +10.6% | REGN higher |
| Debt / equity as of 2026-08-24 | 49.22 | 0.09 | REGN lower |
| Revenue growth (YoY) as of 2026-08-24 | +10.4% | +9.3% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +5.6% | REGN higher |
| Dividend yield as of 2026-08-24 | +4.5% | +0.5% | ABBV higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | 0.22 | 0.15 | |
| 1-year return as of 2026-08-21 close | +26.5% | +39.4% | REGN higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.